Search

Copyright of Der Ophthalmologe is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The article presents a study that confirmed the risks associated with the use of bevacizumab, a monoclonal anti vascular endothelial growth factor (VEGF), in intravitreal injection. A case report of a woman with diabetic retinopathy with decreased visual acuity (VA) is presented. The patient was injected with bevacizumab and remission of the diabetic macular edema (DME) was confirmed without any change in VA. After three weeks, she was diagnosed with anterior ischemic optic neuropathy (AION) which resolved after seven weeks without further treatment.